Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Tuberculosis and HIV investigative Network (THINK), Durban, Kwazulu-Natal, South Africa.
BMC Infect Dis. 2023 Aug 22;23(1):549. doi: 10.1186/s12879-023-08521-4.
Despite the significant progress made in South Africa in getting millions of individuals living with HIV into care, many patients still present or re-enter care with Advanced HIV Disease (AHD). We aimed to estimate the prevalence of AHD among ART-naive and ART-experienced patients in South Africa using studies published between January 2010 and May 2022.
We searched for relevant data on PubMed, CINAHL, Scopus and other sources, with a geographical filters limited to South Africa, up to May 31, 2022. Two reviewers conducted all screening, eligibility assessment, data extraction, and critical appraisal. We synthesized the data using the inverse-variance heterogeneity model and Freeman-Tukey transformation. We assessed heterogeneity using the I statistic and publication bias using the Egger and Begg's test.
We identified 2,496 records, of which 53 met the eligibility criteria, involving 11,545,460 individuals. The pooled prevalence of AHD among ART-naive and ART-experienced patients was 43.45% (95% CI 40.1-46.8%, n = 53 studies) and 58.6% (95% CI 55.7 to 61.5%, n = 2) respectively. The time trend analysis showed a decline of 2% in the prevalence of AHD among ART-naive patients per year. However, given the high heterogeneity between studies, the pooled prevalence should be interpreted with caution.
Despite HIV's evolution to a chronic disease, our findings show that the burden of AHD remains high among both ART-naive and ART-experienced patients in South Africa. This emphasizes the importance of regular measurement of CD4 cell count as an essential component of HIV care. In addition, providing innovative adherence support and interventions to retain ART patients in effective care is a crucial priority for those on ART.
尽管南非在让数百万艾滋病毒感染者获得护理方面取得了重大进展,但仍有许多患者在出现或重新进入高级艾滋病毒病(AHD)时处于该阶段。我们旨在使用 2010 年 1 月至 2022 年 5 月期间发表的研究,估算南非开始接受抗逆转录病毒治疗(ART)和有治疗经验的患者中 AHD 的流行率。
我们在 PubMed、CINAHL、Scopus 和其他来源中搜索相关数据,地理筛选仅限于南非,截至 2022 年 5 月 31 日。两名评审员进行了所有筛选、资格评估、数据提取和关键评估。我们使用逆方差异质性模型和 Freeman-Tukey 变换来综合数据。我们使用 I 统计量评估异质性,并使用 Egger 和 Begg 检验评估发表偏倚。
我们确定了 2496 条记录,其中 53 条符合资格标准,涉及 11545460 人。在开始接受 ART 和有治疗经验的患者中,AHD 的总体流行率分别为 43.45%(95%CI 40.1-46.8%,n=53 项研究)和 58.6%(95%CI 55.7-61.5%,n=2)。时间趋势分析显示,每年开始接受 ART 的患者中 AHD 的流行率下降了 2%。然而,鉴于研究之间存在高度异质性,应谨慎解释总体流行率。
尽管艾滋病毒已演变为慢性病,但我们的研究结果表明,南非开始接受 ART 和有治疗经验的患者中 AHD 的负担仍然很高。这强调了定期测量 CD4 细胞计数作为艾滋病毒护理的重要组成部分的重要性。此外,为了那些接受 ART 的患者,提供创新的依从性支持和干预措施,以将他们留在有效的护理中,是一个至关重要的优先事项。